182120-89-4

Usage

Uses

Used in Pharmaceutical Synthesis:
METHYL 2-((TERT-BUTOXYCARBONYLAMINO)METHYL)OXAZOLE-4-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to protect the amine group during chemical reactions. The t-Boc group allows for selective deprotection, enabling the formation of amines in a controlled manner.
Used in Organic Chemistry:
In the field of organic chemistry, METHYL 2-((TERT-BUTOXYCARBONYLAMINO)METHYL)OXAZOLE-4-CARBOXYLATE is used as a building block for the synthesis of complex organic compounds. Its reactivity and the ease of t-Boc deprotection make it a preferred choice for constructing diverse organic molecules.
Used in Medicinal Chemistry:
METHYL 2-((TERT-BUTOXYCARBONYLAMINO)METHYL)OXAZOLE-4-CARBOXYLATE is utilized in medicinal chemistry for the development of new drugs. Its synthetic utility and the ability to create amines with the removal of the t-Boc group contribute to the design and synthesis of bioactive molecules with potential therapeutic applications.
Used in Drug Development:
In the industry of drug development, METHYL 2-((TERT-BUTOXYCARBONYLAMINO)METHYL)OXAZOLE-4-CARBOXYLATE is employed as a precursor in the creation of novel drug candidates. Its versatility in chemical reactions and the potential to form amines make it a valuable asset in the discovery and optimization of new pharmaceutical agents.

InChI:InChI=1/C11H16N2O5/c1-11(2,3)18-10(15)12-5-8-13-7(6-17-8)9(14)16-4/h6H,5H2,1-4H3,(H,12,15)

Upstream product

• 35150-09-5 N-(tert-butoxycarbonyl)glycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 208465-72-9 methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate 
• 1038926-43-0 2-(2-tert-butoxycarbonylaminoacetylamino)-3-hydroxypropionic acid methyl ester 
• 4530-20-5 BOC-glycine 
• 83661-73-8 methyl (tert-butoxycarbonyl)glycyl-L-serinate 
• 182120-88-3 C₁₁H₁₈N₂O₅ 
• 182120-87-2 2-tert-butoxycarbonylaminoacetimidic acid ethyl ester 
• 871715-69-4 methyl 2-({[(tert-butoxy)carbonyl]amino}methyl)-4,5-dihydro-1,3-oxazole-4-carboxylate 

Downstream Products

• 182120-90-7 2-({[(tert-butoxy)carbonyl]amino}methyl)-1,3-oxazole-4-carboxylic acid 
• 182120-97-4 tert-butyl((4-carbamoyloxazol-2-yl)methyl)carbamate 
• 1203560-66-0 C₃₅H₄₂N₄O₇S 
• 1205666-79-0 C₅₀H₆₄N₄O₉SSi 

Relevant academic research and scientific papers

Solid-Phase-Based Total Synthesis and Stereochemical Assignment of the Cryptic Natural Product Aurantizolicin

The total synthesis and stereochemical assignment of the polyazole cyclopeptide aurantizolicin was achieved by connecting the solution synthesis of building blocks with solid-phase peptide synthesis. Macrothiolactonization and an aza-Wittig reaction provi

Total synthesis of Microcin B17 via a fragment condensation approach

The total synthesis of the 43 amino acid antibacterial peptide Microcin B17 (MccB17) is described. The natural product was synthesized via a convergent approach from a heterocycle-derived peptide and peptide thioester fragments prepared via Fmoc-strategy solid phase peptide synthesis (SPPS). Final assembly was achieved in an efficient manner using two Ag(I)-assisted peptide ligation reactions to afford MccB17 in excellent overall yield.

PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl -mediated disorders.

Singlet Oxygen Photooxidation of Peptidic Oxazoles and Thiazoles

Oxazoles and thiazoles are commonly found moieties in nonribosomal peptides (NRPs) and ribosomally synthesized post-translationally modified peptides (RiPPs), which are important biomolecules present in the environment and in natural waters. From previous studies, they seem susceptible to oxidation by singlet oxygen (1O2); therefore, we designed and synthesized model oxazole- and thiazole-peptides and measured their1O2 bimolecular reaction rate constants, showing slow photooxidation under environmental conditions. We reasoned their stability through the electron-withdrawing effect of the carboxamide substituent. Reaction products were elucidated and support a reaction mechanism involving cycloaddition followed by a series of rearrangements. The first1O2 bimolecular reaction rate constant for a RiPP, the thiazole-containing peptide Aerucyclamide A, was measured and found in good agreement with the model peptide's rate constant, highlighting the potential of using model peptides to study the transformations of other environmentally relevant NRPs and RiPPs.

NOVEL FERROPORTIN INHIBITORS

The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands

We describe the design, synthesis and biological evaluation of a series of novel HIV-1 protease inhibitors bearing isophthalamide derivatives as the P2-P3 ligands. We have investigated a range of acyclic and heterocyclic amides as the extended P2-P3 ligan

Unified azoline and azole syntheses by optimized aza-wittig chemistry

Intramolecular aza-Wittig ring closures were applied to synthesize thiazolines, oxazolines, and imidazolines from β-azido thioester, ester, and amide precursors. The cyclization precursors were obtained from amino acid derivatives. Optimized conditions fo

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

Method for preparing largazole analogs and uses thereof

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.